medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2018, Number 2

Next >>

Arch Neurocien 2018; 23 (2)

Comparative review of central post-stroke and other causes of CNS-originated pain: pathophysiology and treatment

Quintero-Villegas A, Valenzuela-Almada MO, Álvarez-Manzo HS, Calleja-Castillo J

Language: Spanish
References: 154
Page: 6-24
PDF size: 484.69 Kb.


ABSTRACT

Central pain is a common consequence of diverse neurological diseases, such as Stroke, Multiple Sclerosis and Parkinson’s disease. This review article focuses on the pathophysiology of central pain in these diseases as well as its management. The physiology of pain is briefly reviewed followed by a discussion of the physiopathology of post-stroke central pain and its pharmacological and non-pharmacological management. Subsequently, the article reviews and compares central pain caused by multiple sclerosis and Parkinson’s disease regarding pathophysiology, clinical manifestations and treatment. In addition, new pharmacologic and non-pharmacologic strategies for the treatment of central pain caused by these diseases are described, such as deep brain stimulation and transcranial magnetic stimulation.


REFERENCES

  1. Watson JC, Sandroni P. Central Neuropathic Pain Syndromes. Mayo Clin Proc 2016;91(3):372-85.

  2. International Association for the Study of Pain. IASP taxonomy. Recovered December 11th, 2017 from https:// www.iasp-pain.org/Taxonomy#Centralneropathicpain, last updated November 8th, 2017.

  3. Widerström-Noga E, Loeser JD, Jensen TS; et. al. AAPT Diagnostic criteria for central neuropathic pain. J Pain 2017; 18(12):1417-26.

  4. Almeida TF, Roizenblatt S, Tufik S. Afferent pain pathways: a neuroanatomical review. Brain Res 2004;1000:40e56.

  5. Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999;57:1e164.

  6. Scherder E, Wolters E, Polman C, Sergeant J, Swaab D. Pain in Parkinson’s disease and multiple sclerosis: its relation to the medial and lateral pain systems. Neurosci Biobehav Rev 2005;29:1047e56.

  7. Wall PD, Melzack R. Textbook of pain. Sixth edition. Churchill London: Livingstone; 1994

  8. Willis WD, Westlund KN. Neuroanatomy of the pain system and of the pathways that modulate pain. J Clin Neurophysiol 1997;14:2e31.

  9. Head H, Holmes G. Researches into sensory disturbances from cerebral lesions. Brain 1911;34:102–254.

  10. Kim DS, Jung SJ, Nam TS, Jeon YH, Lee DR, Lee JS, et. al. Transplantation of GABAergic neurons from ESCs attenuates tactile hypersensitivity following spinal cord injury. Stem Cells 2010;28:2099–108.

  11. Klit H, Finnerup NB, Jensen TS. Central post-stroke pain: clinical characteristics, pathophysiology and management. Lancet Neurol 2009;8(9):857-68.

  12. Krause T, Brunecker P, Pittl S, Taskin B, Laubisch D, Winter B, et. al. Thalamic sensory strokes with and without pain: differences in lesion patterns in the ventral posterior thalamus. J Neurol Neurosurg Psychiatry 2012;83(8):776-84.

  13. Kumar G, Soni CR. Central post-stroke pain: current evidence. J Neurol Sci 2009; 15;284(1-2):10-7.

  14. Vestergaard K, Nielsen J, Andersen G, Ingeman-Nielsen M, Arendt-Nielsen L, Jensen TS. Sensory abnormalities in consecutive, unselected patients with central post-stroke pain. Pain 1995;61(2):177-86.

  15. Boivie J. Central pain. En: McMahon SB, Koltzenburg M, editors. Wall and Melzack’s Textbook of Pain. London: Elsevier 2006;1057–74.

  16. Siniscalchi A, Gallelli L, De Sarro G, Malferrari G, Santangelo E. Antiepileptic drugs for central post-stroke pain management. Pharmacol Res 2012;65(2):171-5.

  17. Dejerine J, Roussy G. Le syndrome thalamique. Rev Neurol 1906;12:521–32.

  18. Kumar B, Kalita J, Kumar G, Misra UK. Central poststroke pain: review of pathophysiology and treatment. Anesth Analg 2009; 108(5):1645-57.

  19. Kawahara N, Sato K, Muraki M, Tanaka K, Kaneko M, Uemura K. CT classification of small thalamic hemorrhages and their clinical implications. Neurology 1986; 36(2):165-72.

  20. Kumral E, Kocaer T, Ertübey NO, Kumral K. Thalamic hemorrhage. A prospective study of 100 patients. Stroke 1995;26(6):964-70.

  21. Mori S, Sadoshima S, Ibayashi S, Fujishima M, Lino K. Impact of thalamic hematoma on six-month mortality and motor and cognitive functional outcome. Stroke 1995;26(4):620–6

  22. Chung CS, Caplan LR, Han W, Pessin MS, Lee KH, Kim JM. Thalamic haemorrhage. Brain 1996; 119(6):1873–86.

  23. Leijon G, Boivie J. Central post-stroke pain-a controlled trial of amitriptyline and carbamazepine. Pain 1989;36:27-36.

  24. Andersen G, Vestergaard K, Ingeman-Nielsen M, Jensen TS. Incidence of central post-stroke pain. Pain 1995;61(2):187-93.

  25. Bowsher D, Leijon G, Thuomas KA. Central poststroke pain: correlation of MRI with clinical pain characteristics and sensory abnormalities. Neurol 1998;51(5):1352-8.

  26. Widar M, Samuelsson L, Karlsson-Tivenius S, Ahlström G. Long-term pain conditions after a stroke. J Rehabil Med 2002;34(4):165-70.

  27. Kim JS. Central post-stroke pain or paresthesia in lenticulocapsular hemorrhages. Neurol 2003;61(5):679-82.

  28. Oh H, Seo W. A Comprehensive review of central post-stroke pain. Pain Manag Nurs 2015;16(5):804-18.

  29. Hansen AP, Marcussen NS, Klit H, Andersen G, Finnerup NB, Jensen TS. Pain following stroke: a prospective study. Eur J Pain 2012;16(8):1128-36.

  30. Lampl C1, Yazdi K, Röper C. Amitriptyline in the prophylaxis of central poststroke pain. Preliminary results of 39 patients in a placebo-controlled, long-term study. Stroke 2002;33(12):3030-2.

  31. Frese A, Husstedt IW, Ringelstein EB, Evers S. Pharmacologic treatment of central post-stroke pain. Clin J Pain. 2006;22(3):252-60.

  32. Bowsher D. Central post-stroke (thalamic syndrome) and other central pains; American Journal of Hospice and Palliative Care 1999; 59:16e4

  33. Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol 2005;96(6):399-409.

  34. Shimodozono M, Kawahira K, Kamishita T, Ogata A, Tohgo S, Tanaka N. Reduction of central poststroke pain with the selective serotonin reuptake inhibitor fluvoxamine. Int J Neurosci 2002; 112(10):1173-81.

  35. Vranken JH, Hollmann MW, Van der Vegt MH, Kruis MR, Heesen M, Vos K, et al. Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial. Pain 2011; 152(2):267-73.

  36. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001; 56(2):184-90.

  37. Nicholson BD. Evaluation and treatment of central pain syndromes. Neurol 2004;62(5 Suppl 2):S30-6.

  38. Kim J. Pharmacological management of central post-stroke pain: a practical guide. CNS Drugs 2014;28(9):787-97.

  39. Kim J, Bashford G, Murphy TK, Martin A, Dror V, Cheung R. Safety and efficacy of pregabalin in patients with central post-stroke pain. Pain 2011;152(5):1018-23.

  40. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348(13):1223-32.

  41. Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine in central pain: a randomized placebo-controlled study. Neurol 2002;58(4):554-63.

  42. Bainton T, Fox M, Bowsher D, Wells C. A double-blind trial of naloxone in central post-stroke pain. Pain 1992;48(2):159-62.

  43. Vo T, Rice A, Dworkin H. Non-steroidal anti-inflammatory drugs for neuropathic pain: How do we explain continued widespread use?. Pain 2009; 143(3): 169-71.

  44. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150(3):573-81.

  45. Matsuura W, Harada S, Tokuyama S. Effects of adjuvant analgesics on cerebral ischemia-induced mechanical allodynia. Biol Pharm Bull 2016;39(5):856-62.

  46. Attal N, Gaudé V, Brasseur L, Dupuy M, Guirimand F, Parker F, et. al. Intravenous lidocaine in central pain: a double-blind, placebo-controlled, psychophysical study. Neurol 2000;54(3):564-74.

  47. Fisher K, Hagen NA. Analgesic effect of oral ketamine in chronic neuropathic pain of spinal origin: a case report. J Pain Symptom Manage 1999;18(1):61-6.

  48. Vick PG, Lamer TJ.Treatment of central post-stroke pain with oral ketamine. Pain 2001;92(1-2):311-3.

  49. Nauta HJ, Hewitt E, Westlund KN, Willis Jr WD. Surgical interruption of a midline dorsal column visceral pain pathway. Case report and review of the literature. J Neurosurg 1997;86(3):538–42.

  50. Hirshberg RM, Al-Chaer ED, Lawand NB, Westlund KN, Willis WD. Is there a pathway in the posterior funiculus that signals visceral pain?. Pain 1996; 67(2-3):291–305.

  51. Triggs WJ, Beric A. Dysaesthesiae induced by physiological and electrical activation of posterior column afferents after stroke. J Neurol Neurosurg Psychiatry 1994; 57(9):1077–80.

  52. Peyron R, Garcia-Larrea L, Gregoire MC, Costes N, Convers P, Lavenne F, et. al. Haemodynamic brain responses to acute pain in humans: sensory and attentional networks. Brain 1999; 122(9):1765–80.

  53. Lenz FA, Kwan HC, Martin R, Tasker R, Richardson RT, Dostrovsky JO. Characteristics of somatotopic organization and spontaneous neuronal activity in the region of the thalamic principal sensory nucleus in patients with spinal cord transection. J Neurophy 1994;72(4):1570–87.

  54. Peyron R, Garcia-Larrea L, Deiber MP, Cinotti L, Convers P, Sindou M, et. al. Electrical stimulation of precentral cortical area in the treatment of central pain: electrophysiological and PET study. Pain 1995;62(3):275–86.

  55. Wiesenfeld-Hallin Z, Aldskogius H, Grant G, Hao JX, Hokfelt T, Xu XJ. Central inhibitory dysfunctions: mechanisms and clinical implications. Behav Brain Sci 1997;20(3):420-5 discussion 35-513.

  56. Seo W, Oh H. Comparisons of acute physiological parameters influencing outcome in patients with traumatic brain injury and hemorrhagic stroke. Worldviews Evid Based Nurs 2009;6(1):36-43.

  57. Treede RD, Jensen TS, Campbell JN, et. al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurol 2008;70:1630–35.

  58. Solaro C, Trabucco E, Messmer, Uccelli M. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep 2013;13(1):320.

  59. Svendsen KB, Jensen TS, Hansen HJ, Bach FW. Sensory function and quality of life in patients with multiple sclerosis and pain. Pain 2005;114(3):473-81.

  60. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurol 2005; 65(6):812-9.

  61. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis--prevalence and clinical characteristics. Eur J Pain 2005; 9(5):531-42.

  62. O'Connor AB, Schwid SR, Herrmann DN, Markman JD, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 2008;137(1):96-111.

  63. Thorburn KC, Paylor JW, Webber CA, Winship IR, Kerr BJ. Facial hypersensitivity and trigeminal pathology in mice with experimental autoimmune encephalomyelitis. Pain 2016;157(3):627-42.

  64. Frezel N, Sohet F, Daneman R, Basbaum AI, Braz JM. Peripheral and central neuronal ATF3 precedes CD4+ T-cell infiltration in EAE. Exp Neurol 2016; 283(A): 224–234.

  65. Olechowski CJ, Truong JJ, Kerr BJ. Neuropathic pain behaviours in a chronic-relapsing model of experimental autoimmune encephalomyelitis (EAE). Pain 2009;141(1-2):156-64.

  66. Max M, Hagen NA. Do changes in brain sodium channels cause central pain?. Neurol 2000;54(3).

  67. Collin SM, Nijs J, Meeus M, et. al. Endogenous pain facilitation rather than inhibition differs between people with chronic fatigue Syndrome, Multiple Sclerosis, and controls: an observational study. Pain Physician 2017; 20(4):E489-E497.

  68. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007;( 4):CD005454.

  69. Brown TR, Slee A. A randomized placebo-controlled trial of duloxetine for central pain in multiple sclerosis. Int J MS Care 2015;17(2):83-9.

  70. Houtchens MK, Richert JR, Sami A. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler 1997;3(4): 250-3.

  71. Solaro C, Boemker M, Tanganelli P. Pregabalin for treating paroxysmal symptoms in multiple sclerosis: a pilot study. J Neurol 2009;256(10):1773-4.

  72. Kaiman S, Österberg A, Sörensen J, Boivie J, Bertler A. Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with IV morphine. Euro J Pain 2002;6(1).

  73. Herman RM, D'Luzansky SC, Ippolito R. Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. Clin J Pain 1992;8(4):338-45.

  74. Sadiq SA, Poopatana CA. Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity. J Neurol 2007;254(10):1464-5.

  75. Chiurchiů V, van der Stelt M, Centonze D, et. al. The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: clues for other neuroinflammatory diseases. Prog Neurobiol 2018; 160:82-100.

  76. Isagulyan ED, Tomsky AA, Dekopov AV, Salova EM, Troshina EM, Dorokhov EV, et. al. Results of motor cortex stimulation in the treatment of chronic pain syndromes Zh Vopr Neirokhir Im N N Burdenko 2015;79(6):46-60

  77. Cordella R, Franzini A, La Mantia L, Marras C, Erbetta A, Broggi G. Hypothalamic stimulation for trigeminal neuralgia in multiple sclerosis patients: efficacy on the paroxysmal ophthalmic pain. Mult Scler 2009;15(11):1322-8

  78. Mori F, Codecŕ C, Kusayanagi H, Monteleone F, Buttari F, Fiore S, et. al. Effects of anodal transcranial direct current stimulation on chronic neuropathic pain in patients with multiple sclerosis. J Pain 2010;11(5):436-42.

  79. Koch G, Mori F, Marconi B, Codecŕ C, Pecchioli C, Salerno S, et. al. Changes in intracortical circuits of the human motor cortex following theta burst stimulation of the lateral cerebellum. Clin Neurophysiol 2008;119(11):2559-69.

  80. Lefaucheur JP, André-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, et. al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014;125(11):2150-206.

  81. Fil R, Cano-de-la-Cuerda E, Munoz-Hellin L, Vela M, Ramiro-Gonzalez C, Fernandez-de-Las- Peńas. Pain in Parkinson disease: a review of the literature, Parkinsonism and related disorders 2013;1(19):285-94; discussion 285.

  82. Nčgre-Pagčs L, Regragui W, Bouhassira D, Grandjean H, Rascol O, DoPaMiP Study Group. Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord 2008;23:1361e9.

  83. Ford B. Pain in Parkinson’s disease. Mov Disord 2010;1:S98e10.

  84. Wasner G, Deuschl G. Pains in Parkinson disease-many syndromes under one umbrella. Nature Rev Neurol 2012; 8(5): 284–94.

  85. Snider SR, Fahn S, Isgreen WP, Cote LJ. Primary sensory symptoms in parkinsonism. Neurol 1976;26:423e9.

  86. Clifford TJ, Warsi MJ, Burnett CA. Burning mouth in Parkinson’ disease sufferers. Gerodontol 1998;15:73e8.

  87. Ford B, Louis ED, Greene P, Fahn S. Oral and genital pain syndromes in Parkinson’s disease. Mov Disord 1996;11:421e6.

  88. Kulakowska A, Pogorzelski R, Borowik H, Drozdowski W. Wearing off phenomenon presenting with features of paroxysmal abdominal pain. Neurologia i Neurochirurgia Polska 2002; 37(5):197-202, 2003.

  89. Zambito S, Tinazzi M, Vitaliani R, Recchia S, Fabris F, Marchini C, et. al. Spontaneous pain, pain threshold, and pain tolerance in Parkinson’s disease J Neurol 2011; 258(4):627-33

  90. Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, et. al. Effect of levodopa on pain threshold in Parkinson’s disease: a clinical and positron emission tomography study. Mov Disord 2005;20:1557-63.

  91. Djaldetti R, Shifrin A, Rogowski Z, et. al. Quantitative measurement of pain sensation in patients with Parkinson’s disease. Neurol 2004;62(12):2171–75.

  92. Urakami K, Takahashi K, Matsushima E, Sano K, Nishikawa S, Takao T. The threshold of pain and neurotransmitter’s change on pain in Parkinson’s disease. Jpn J Psychiat Neurol 1990;44:589–93.

  93. Felice VD, Quigley EM, Sullivan AM, O'Keeffe GW, O'Mahony. Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms. Parkinsonism Relat Disord 2016;27:1-8.

  94. Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain 1995; 60:3e38.

  95. Kuraishi Y, Fukui K, Shiomi H, Akaike A, Takagi H. Microinjection of opioids into the nucleus reticularis gigantocellularis of the rat: analgesia and increase in the normetanephrine level in the spinal cord. Biochem Pharmacol 1978;27:2756e8.

  96. Gebhart GF. Descending modulation of pain. Neurosci Biobehav Rev 2004; 27:729e37.

  97. Voisin DL, Guy N, Chalus M, Dallel R. Nociceptive stimulation activates locus coeruleus neurons projecting to the somatosensory thalamus in the rat. J Physiol 2005; 566:929e37.

  98. Pertovaara A. Noradrenergic pain modulation. Prog Neurobiol 2006; 80:53e83

  99. Benarroch EE. Descending monoaminergic pain modulation: bidirectional control and clinical relevance. Neurol 2008;71:217e21.

  100. Clark FM, Proudfit HK. Projections of neurons in the ventromedial medulla to pontine catecholamine cell groups involved in the modulation of nociception. Brain Res 1991;540:105e15.

  101. Cury RG, Galhardoni R, Fonoff ET, et. al. Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. Eur J Pain 2016;20(2):151-65.

  102. Ha AD, Jankovic J. Pain in Parkinson’s disease. Mov Disord 2012; 27(4):485–91.

  103. Holloway RG1, Shoulson I, Fahn S, Kieburtz K, Lang A, et. al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61(7):1044-53.

  104. Barone P, Poewe W, Albrecht S, et. al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9:573–80.

  105. Kassubek J, Chaudhuri KR, Zesiewicz T, et. al. Rotigotine transdermal system and evaluation of pain inpatients with Parkinson’s disease: a post hoc analysis of the RECOVER study. BMC Neurol 2014;14–42.

  106. Geroin C, Gandolfi M, Bruno V, Smania N, Tinazzi M. Integrated approach for pain management in Parkinson disease.Curr Neurol Neurosci Rep 2016;16:28.

  107. Perez-Lloret S, Rey MV, Dellapina E, Pellaprat J, Brefel-Courbon C, Rascol O. Emerging analgesic drugs for Parkinson’s disease. Expert Opin Emerg Drugs 2012;17:157–71.

  108. Ghoche R. The conceptual framework of palliative care applied to advanced Parkinson’s disease. Parkinsonism Relat Disord 2012;18:S2–5.

  109. Djaldetti R, Yust-Katz S, Kolianov V, Melamed E, Dabby R. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007; 30:201–5.

  110. Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord 2007; 22:2097–103.

  111. Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord 2001;16:907–13.

  112. Tassorelli C, De Icco R, Alfonsi E, et. al. Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study. Parkinsonism Relat Disord 2014;20:1140–4

  113. Sim WS. Application of botulinum toxin in pain management. Korean J Pain 2011;24:1–6.

  114. Loher TJ, Burgunder JM, Weber S, Sommerhalder R, Krauss JK. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002;73:395–9.

  115. Deep-Brain Stimulation for Parkinson’s disease study group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med 2001;345:956–63.

  116. Kim HJ, Paek SH, Kim JY. Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol 2008; 255:1889–94

  117. Oakley JC, Prager JP. Spinal cord stimulation: mechanisms of action. Spine 2002;27:2574–83.

  118. Fénelon G, Goujon C, Gurruchaga JM. Spinal cord stimulation for chronic pain improved motor function in a patient with Parkinson’s disease. Parkinsonism Relat Disord 2012;18:213–4.

  119. Cioni B. Motor cortex stimulation for Parkinson's disease. Acta Neurochir Suppl 2007;97(2):233-8.

  120. Arle JE, Shils JL. Motor cortex stimulation for pain and movement disorders. Neurotherapeutics 2008; 5(1)37–49.

  121. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson’s disease. J Neurosurg 1992; 76:53–61.

  122. Honey CR, Stoessl AJ, Tsui JK, Schulzer M, Calne DB. Unilateral Pallidotomy for reduction of parkinsonian pain. J Neurosurg 1999; 91:198–201

  123. De Rodrigues PF, Teixeira-Salmela LF, de Coelho MF, de Rocha BP, Cardoso F. Impact of an exercise program on physical, emotional, and social aspects of quality of life of individuals with Parkinson’s disease. Mov Disord 2006; 21:1073–7.

  124. Reuter I, Mehnert S, Leone P, Kaps M, Oechsner M, Engelhardt M. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson’s disease. J Aging Res 2011; ID 232473

  125. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311:1670.

  126. Indaco A, Carrieri PB. Amitriptyline in the treatment of headache in patients with Parkinson's disease: a doubleblind placebo-controlled study. Neurol 1988; 38(11):1720-2.

  127. Jensen ST, Anticonvulsants in neuropathic pain: rationale and clinical evidence European Journal of Pain 2002; Suppl. A(6):61-68.

  128. Miyasaki JM, Martin W, Suchowersky O, et. al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the quality standards subcommittee of the american academy of Neurology. Neurol 2002; 58:11.

  129. Trenkwalder C, Martinez-Martin P, Rascol O, et. al. Prolonged release oxycodone/naloxone (OXN PR) is associated with treatment benefits in patients with severe Parkinson’s disease (PD)- related pain: Results from a randomised, controlled trial. Mov Disord 2015;30:335.

  130. Breuer B, Pappagallo M, Knotkova H. A randomized double-blind, placebo-controlled two period crossover pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther 2007; 29: 2022-30.

  131. McCleane G. Lamotrigine can reduce neurogenic pain associated with multiple sclerosis. Clin J Pain 1998; 14 (3): 269-70.

  132. Rossi S, Mataluni G, Codeca C. Effects of levetiracetam on chronic pain in multiple sclerosis: results of a randomized placebo-controlled study. Eur J Neurol 2009;16:360-6.

  133. Solaro C, Brichetto G, Battaglia MA, et. al. Antiepileptic medications in multiple sclerosis: adverse effects in a three year follow-up study. Neurol Sci 2005; 25(6):307-10.

  134. Solaro C, Messmer UM. Pharmacological management of pain in patients with Multiple Sclerosis. Drugs 2010;70(10):1245-54.

  135. Jungehulsing GJ, Israel H, Safar N, Taskin B, Nolte CH, Brunecker P, Wernecke KD, Villringer A. Levetiracetam in patients with central neuropathic post-stroke pain-a randomized, double-blind, placebo-controlled trial. Eur J Neurol 2013; 20(2):331-7.

  136. Wiffen PJ, Derry S, Moore RA, Lunn MP. Levetiracetam for neuropathic pain in adults. Cochrane database Syst Rev 2014; (7):CD010943.

  137. Zajicek J, Fox P, Sanders H Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003 Nov 8;362(9395):1517-26.

  138. Owen SL, Green AL, Nandi DD; Deep brain stimulation for neuropathic pain. Acta Neurochir Suppl 2007;97(2):111-6.

  139. Alves RV, Asfora WT. Deep brain stimulation for ejerine-Roussy syndrome: case report. Minim Invasive Neurosurg 2011; 54(4):183-6.

  140. Mallory GW, Abulseoud O, Hwang SC; The nucleus accumbens as a potential target for central poststroke pain. Mayo Clin Proc. 2012; 87(10):1025-31.

  141. Nguyen JP, Nizard J, Keravel Y, Invasive brain stimulation for the treatment of neuropathic pain. Nat Rev Neurol. 2011 20; 7(12):699-709

  142. Nizard J, Raoul S, Nguyen JP. Invasive stimulation therapies for the treatment of refractory pain. Discov Med 2012; 14(77):237-46.

  143. Herregodts P, Stadnik T, De Ridder F, et. al. Cortical stimulation for central neuropathic pain: 3-D surface MRI for easy determination of the motor cortex. Acta Neurochir Suppl 1995; 64:132-5.

  144. Fagundes-Pereyra WJ, Teixeira MJ, Reyns N, et. al. Motor cortex electric stimulation for the treatment of neuropathic pain. Arq Neuropsiquiatr 2010; 68(6):923-9.

  145. Lazorthes Y, Sol JC, Fowo S, et. al. Motor cortex stimulation for neuropathic pain. Acta Neurochir Suppl 2007; 97(2):37-44.

  146. Cruccu G1, Aziz TZ, Garcia-Larrea L, et. al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol. 2007;14(9):952-70.

  147. Fukui S, Shigemori S, Nosaka S. Central pain associated with low thalamic blood flow treated by electroconvulsive therapy. J Anesth 2002;16(3):255-7.

  148. Fukui S, Shigemori S, Yoshimura A, et. al. Chronic pain with beneficial response to electroconvulsive therapy and regional cerebral blood flow changes assessed by single photon emission computed tomography. Reg Anesth Pain Med 2002; 27(2):211-3.

  149. Hayashi M, Chernov MF, Taira T, et. al. Outcome after pituitary radiosurgery for thalamic pain syndrome. Int J Radiat Oncol Biol Phys 2007; 69(3):852-7.

  150. Conti A, Pontoriero A, Iatě G, et. al. Frameless stereotactic radiosurgery for treatment of Multiple Sclerosis-Related Trigeminal Neuralgia. World Neurosurg 2017;103:702-12.

  151. Alvarez-Pinzon AM, Wolf AL, Swedberg HN, et. al. Comparison of percutaneous Retrogasserian Balloon Compression and Gamma Knife Radiosurgery for the treatment of trigeminal neuralgia in Multiple Sclerosis. World Neurosurg 2017; 97:590-4.

  152. Ramachandran VS, McGeoch PD, Williams L, et al. Rapid relief of thalamic pain syndrome induced by vestibular caloric stimulation. Neurocase. 2007; 13(3):185-8.

  153. McGeoch PD, Williams LE, Lee RR, et. al. Behavioural evidence for vestibular stimulation as a treatment for central post-stroke pain. J Neurol Neurosurg Psychiatry 2008; 79(11):1298-301.

  154. Fénelon G, Goujon C, Gurruchaga JM, et. al. Spinal cord stimulation for chronic pain improved motor function in a patient with Parkinson's disease. Parkinsonism Relat Disord 2012 ;18(2):213-4.




2020     |     www.medigraphic.com